Get the Stockscreener App
24.31
3.38%
-0.85
Ascentage Pharma Group International Adr stock is traded at $24.31, with a volume of 9,839.
It is down -3.38% in the last 24 hours and up +27.95% over the past month.
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.
See More
Previous Close:
$25.16
Open:
$24.19
24h Volume:
9,839
Relative Volume:
0.19
Market Cap:
$2.22B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-4.59%
1M Performance:
+27.95%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$24.19
$24.50
1-Week Range:
$23.67
$26.00
52-Week Range:
$17.09
$26.50
Ascentage Pharma Group International Adr Stock (AAPG) Company Profile
Name
Ascentage Pharma Group International Adr
Sector
Industry
Phone
-
Address
-
Compare AAPG with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AAPG
Ascentage Pharma Group International Adr
|
24.31 | 2.22B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Ascentage Pharma Group International Adr Stock (AAPG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-27-25 | Initiated | JP Morgan | Overweight |
Ascentage Pharma Group International Adr Stock (AAPG) Latest News
Bitdeer Tech And Tempus AI Are Among Top 18 Mid-Cap Gainers Last Week (Apr 21-Apr 25): Are The Others In Your Portfolio? - Benzinga
Ascentage Pharma Files Annual Report, Announces Shareholder Meeting By Investing.com - Investing.com South Africa
Ascentage Pharma Files Annual Report, Announces Shareholder Meeting - Investing.com
JPMorgan sets Ascentage Pharma stock to Overweight, $27 target - Investing.com
Takeda Pharmaceutical Company (TKPYY) Stock: Strategic Focus on Oncology and Growth Opportunities - Value the Markets
Ascentage Pharma to Announce 2024 Financial Results and Corporate Update - TipRanks
Ascentage Has First U.S. Biotech IPO of 2025, Raising $126M to Bring Its Cancer Meds to the World - Dealbreaker
Ascentage Pharma IPO opens flat - Investing.com
Ascentage Pharma shares slide ahead of ADS debut on Nasdaq - Investing.com
Ascentage prices first biotech IPO of 2025, raising $126M - BioPharma Dive
Ascentage Pharma sets terms for $149 million US IPO - The Pharma Letter
Takeda-backed Ascentage Pharma files for $100M IPO (IPO:NYSEARCA) - Seeking Alpha
Ascentage Pharma Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering of American Depositary Shares - PR Newswire
Takeda, Ascentage Pharma Sign Option Agreement - Contract Pharma
Capital Markets - Wilson Sonsini
Morningstar | Empowering Investor Success - Morningstar
ADVFN | Live Stock, Options & Crypto Market Data, Trading Tools & Community - ADVFN Logo
Ascentage Pharma Group International Adr Stock (AAPG) Financials Data
There is no financial data for Ascentage Pharma Group International Adr (AAPG). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.84%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):